H. Lundbeck A/S (0ND5.L)

35,78 +0,20 (+0,56%) Börsenschluss: 05:54PM BST

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 5.681

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Charl van Zyl	President & CEO	36,9M	N/A	1967
Mr. Joerg Hornstein	CFO & Executive VP of Corporate Functions	8,5M	N/A	1977
Mr. Lars Bang	Executive Vice President of Product Development & Supply	7,9M	N/A	1962
Dr. Per Johan Luthman	Executive Vice President of Research & Development	8,8M	N/A	1959
Dr. Tarek Samad Ph.D.	Senior VP & Head of Research	N/A	N/A	N/A
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/A	N/A	N/A
Ms. Tine Ostergaard Hansen	Senior Vice President of Corporate Communications & Public Affairs	N/A	N/A	N/A
Ms. Dianne Holto	Executive Vice President of People & Organization	N/A	N/A	1973
Mr. Ole Chrintz	Senior Vice President of International Markets	N/A	N/A	1958
Dr. Rupert Sandbrink M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	1964

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in DKK.

Beschreibung

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Corporate Governance

H. Lundbeck A/Ss ISS Governance QualityScore, Stand 1. April 2024, lautet 3. Die grundlegenden Scores sind Audit: 4, Vorstand: 5, Shareholderrechte: 9, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.